热景生物：创新药SGC001注射液Ib期临床研究完成所有受试者观察并揭盲

Core Viewpoint - The announcement from Hotgen Biotech (688068.SH) highlights the successful completion of clinical trials for its innovative drug SGC001, indicating potential for acute myocardial infarction treatment [1] Group 1: Clinical Trial Results - SGC001 injection has completed Phase Ia clinical research in healthy volunteers and Phase Ib clinical observation in patients with ST-segment elevation myocardial infarction [1] - No grade 3 or higher adverse events were reported across all dosage groups, and preliminary efficacy results align with expectations [1] - The drug is currently in the data statistical analysis phase, focusing on its application for emergency treatment of acute myocardial infarction patients [1] Group 2: Market Context - There are currently no antibody drugs for acute myocardial infarction (AMI) in clinical research or approved for market, positioning SGC001 as a potentially unique offering in this therapeutic area [1]